Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Rare Hematological Malignancies
This hugely practical work will be a bible in the pocket of hematologists and other practitioners everywhere, covering as it does malignant hematologic diseases that physicians will only occasionally see. It provides accurate, up-to-date information on the disease biology as well as practical recommendations concerning disease management. Information concerning these diseases, and particularly regarding their management, can be extremely difficult to find. Not any more.
The Oncogenomics Handbook
An integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following a systems biology approach, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including Ritux an, Erbitux, Gleevec Herceptin, Avastin, ABX-EGF, Velcade, Kepivance, Iressa, Tarceva, and Zevalin are addressed. Highlights include cancer genomics, pharmacogenomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation.
Hodgkin Lymphoma
This book provides a well-illustrated, comprehensive, and up-to-date account of Hodgkin lymphoma. Epidemiology, pathogenesis, and the role of the microenvironment are examined in detail. The initial clinical evaluation and use of staging systems are fully discussed, and prognostic factors are carefully considered. The various treatment options for first-line and relapsed Hodgkin lymphoma are presented, including the newly available treatments for recurrent disease and the management required in special clinical circumstances. Given the very high cure rates and the young age of many patients, there is an increasing need to develop better individually tailored treatment strategies that will help to avoid both early and late side-effects of treatment. Such strategies receive due attention, and clear guidance is provided on the handling of Hodgkin survivors. This book will be of great value to hematologists, oncologists, and all others with an interest in Hodgkin lymphoma.
Lymphomas
Emerging Cancer Therapeutics is a trinary hard cover periodical that is designed to provide an up-to-date evidence-based review of a dedicated emerging cancer therapy topic of interest to clinicians and scientists involved in the care of patients receiving cancer treatment. It will serve as both a reference and instructional tool for students, housestaff, fellows, practicing clinical oncologists, radiation oncologists, surgical oncologists, cancer biologists, and interdisciplinary colleagues throughout the oncology spectrum. With contributions from internationally recognized experts, Lymphomas combines chapters on the evolving role of established therapies such as stem cell transplantation w...
60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center
This unique book provides a retrospective analysis of the changes in survival outcomes at the University of Texas, M.D. Anderson Cancer Center over the past six decades. Since opening its doors in 1944, M.D. Anderson has kept a continuous, uninterrupted data repository of the treatment and outcomes of each of its patients. It is this visionary database from the center’s tumor registry which makes this groundbreaking book possible. Tracking results across time, this book shows radical shifts in outcomes trends, where great progress has been made, and where there is still a long way to go, and offers a snapshot into the parallel history of developments in care. Such data is crucial to inform...
Drug Resistance in Leukemia and Lymphoma III
Cellular drug resistance is a major limitation to the success of chemotherapy of leu kemia and lymphoma. The importance of this has now been recognized by both clinicians and scientists. It is of utmost importance to bridge the gap between laboratory and clinic in this field of research. This is the main purpose of the series of International Symposia on Drug Resistance in Leukemia and Lymphoma. These are held every three years in Am sterdam, The Netherlands, since 1992. This book contains the proceedings of the third of these meetings, organised in 1998. The book covers all important aspects of drug resistance in leukemia and lymphoma, both in the form of extensive reviews as in manuscripts...
Hematological Malignancies In Children, Adolescents And Young Adults (With Cd-rom)
Bringing together intellectual and scientific experts from pediatrics, adolescent medicine, general medicine, pathology, biology, nursing and psychology, this book is the first of its kind to cover the topics of leukemias and lymphomas in young patients ranging from infants to young adults. The content is organized and subdivided into four major sections — under the main headings of General Considerations, Pathobiology, Clinical Manifestations and Treatment, and Supportive Care and Complications — for ease of reference to readers. Hematological Malignancies in Children, Adolescents and Young Adults presents a comprehensive multidisciplinary review of the field of hematological malignancies and brings forth illuminating perspectives from an internationally recognized group of leading authorities in the field.
Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics
In the last decade, there has been a remarkable explosion of knowledge in hematologic cancer from basic molecular biology and pathology to clinical therapy. This has led to many new advance and insights in the understanding of pathobiology of malignant hematology. New knowledge of disease molecular pathology, cytogenetic, epigenetic and genomic alterations have provided new strategies to attack and eradicate tumor cells at molecular level and significantly impacted our current therapeutics for hematological malignancies. The recent and ongoing rapid expansion of knowledge in this area has become extensive, dynamic and diffuse over the literature and research publications. This has led to the...
